"As promised, my slides from the meeting I posted on 2 days ago."
"The case study is the one I used at the ABN to warn against simply using clinical markers of disease activity to monitor a response to a DMT. We have to start using MRI and to act on it when we see that MSers are not responding. I also made the point that we can't let MSers cycle through multiple 1st-line therapies that are only moderately effective we need to get them onto highly active DMTs as soon as possible. Treat early! Treat aggressively!"